Prodromal Parkinson's Disease

Kiel, Germany – June 14-15, 2019

Prodromal Parkinson's Disease
Kiel, Germany – June 14-15, 2019

Prodromal Parkinson's Disease takes place in Kiel, Germany, June 14-15, 2019.Course Directors

Daniela Berg, MD, PhD, Christian-Albrechts University Kiel, Germany
Matej Skorvanek MD, PhD, University of P. J. Safarik in Kosice, Slovakia
Eva Schäffer, MD, Christian-Albrechts, University Kiel, Germany

Course Description

The concept of Prodromal Parkinson’s disease (PD) is gaining increased attention as it has become evident that there are several risk and clinical markers (prodromal markers) that may occur years before the cardinal motor symptoms allow clinical diagnosis. The hope for an earlier diagnosis as basis for early therapeutic intervention has become even more meaningful in the light of the current development of causal therapies including antibody and anti-oxidative therapies as well as specific approaches for mono-genetic forms of PD. A statistical model has been developed that allows the calculation of the individual risk to develop PD.

These new concepts, their backgrounds, implementation, chances and possible confounders and limitations need to be understood and properly applied.

This course is intended for neurologists, residents in neurology and basic scientists interested in prodromal PD. During the course, evidence-based results and speakers’ experiences with risk and prodromal markers, cohorts, assessments and calculations in prodromal PD, as well as emerging treatments will be reviewed from the basic science as well as clinical point of view. The course will also include hands-on sessions on several aspects of prodromal PD assessment. The meeting will be concluded with an interactive panel discussion on future steps. Poster presentations will allow participants presentation of their recent work in the field of prodromal PD and discussion of novel ideas.

Recommended Audience

This course is intended for neurologists, residents in neurology and basic scientists interested in prodromal PD.

Learning Objectives 
  • Recognize the currently known risk and prodromal markers of prodromal PD
  • Discuss the possible approaches to identify individuals in the prodromal phase
  • Discuss the emerging treatment strategies for prodromal PD



University of Kiel
Department of Neurology
Kiel, Germany

Accreditation Statement

The Prodromal Parkinson’s Disease, Kiel, Germany, 14/06/2019-15/06/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found on this website.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Visa Statement

MDS is able to provide participants with a Letter of Support and any course-related documentation needed to assist in obtaining a visa. Please note that MDS is unable to contact the Embassy on your behalf. It is the responsibility of each participant to make the necessary arrangements related to this process. However, if the official handling your application needs further clarification, please have them contact

dpg logo

This course is presented in collaboration with The German Society for Parkinson’s Disease (DPG).


Prodromal Parkinson's Disease is compliant with MedTech Europe Code of Ethical Business Practice.


We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice